Jan 18,2022 / News / Webinar
We unpack a recent judgement concerning a tender process and what that reveals about an approach to reviewing the outcome of a tender process. We also look at the status of the National Health Insurance Scheme and what is promised for 2022 as well as the implications of the current “roadmap” for complementary medicines, manufacturers, and importers of those medicines.
Please join Neil Kirby, who is a Director and Head of Healthcare & Life Sciences practice at Werksmans, together with Helen Michael, Director and Boitumelo Moti, Associate, as we deliberate on these interesting developments.
08:30 – 08:35 | Welcome and Introduction – Neil Kirby, Director, and Head of Healthcare Life Sciences, Werksmans Incorporated
08:35 – 09:05 | Remedyless’ Review – a cautionary tale – An analysis of the recent High Court judgement in Ilex – Helen Michael, Director, Healthcare & Life Sciences Practice Area
09:05 – 09:35 | Regulation by guideline – The status of the regulation of complementary medicines in the current legislative landscape – Boitumelo Moti, Associate, Healthcare & Life Sciences Practice Area
09:35 – 10:05 | National Health Insurance Scheme – What are we expecting in 2022? – Neil Kirby
10:05 – 10:20 | Questions and closing discussion
RSVP: Click here to RSVP
© 2022 Werksmans Attorneys, All rights reserved.
